Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04326439 · ClinicalTrials.gov registry record · Phase 2
AflacLL1901 (CHOA-AML)
A Phase 2 study, sponsored by Emory University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT04326439 is a Phase 2 study that was terminated before completion, run by Emory University. The registered enrollment target is 8 participants.
The verdict
NCT04326439, a Phase 2 study, was terminated before completion, sponsored by Emory University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
The investigators propose to study an Aflac-AML chemotherapy backbone prospectively to validate its use in all pediatric AML and to further evaluate the cardiotoxicity with this approach for low risk AML.
Interventions
- DRUG Etoposide
- DRUG Cytarabine
- DRUG Daunorubicin
- DRUG Gemtuzumab ozogamicin
- DRUG Erwinase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2020-01-24 |
| Est. Completion | 2022-03-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04326439
The ClinicalTrials.gov registry entry for NCT04326439 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Etoposide is the first listed.
NCT04326439 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04326439 about?
NCT04326439 is a clinical study titled "AflacLL1901 (CHOA-AML)". The investigators propose to study an Aflac-AML chemotherapy backbone prospectively to validate its use in all pediatric AML and to further evaluate the cardiotoxicity with this approach for low risk AML.
What is the current status of trial NCT04326439?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2020-01-24. Estimated completion is 2022-03-15.
What interventions are being tested in trial NCT04326439?
The interventions under investigation include: Etoposide (DRUG), Cytarabine (DRUG), Daunorubicin (DRUG), Gemtuzumab ozogamicin (DRUG), Erwinase (DRUG).
Who is sponsoring clinical trial NCT04326439?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.